Compare Stocks → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:NXGLNASDAQ:QNRXNYSE:RMED Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNXGLNEXGEL$2.65-0.7%$2.43$1.25▼$3.14$15.16M0.6521,845 shs432 shsQNRXQuoin Pharmaceuticals$0.86-1.1%$2.48$0.80▼$12.00$852K1.88617,229 shs50,920 shsRMEDRa Medical Systems$0.73$0.52▼$11.14$3.19M-0.03197,480 shs77,500 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNXGLNEXGEL-1.48%-2.91%+16.59%+20.81%+96.32%QNRXQuoin Pharmaceuticals+4.19%-3.33%-67.66%-83.11%-84.85%RMEDRa Medical Systems0.00%0.00%0.00%0.00%-61.92%$25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNXGLNEXGEL0.6611 of 5 stars0.03.00.00.02.93.30.0QNRXQuoin Pharmaceuticals1.9488 of 5 stars3.53.00.00.03.00.00.6RMEDRa Medical SystemsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNXGLNEXGELN/AN/AN/AN/AQNRXQuoin Pharmaceuticals3.00Buy$4.00365.01% UpsideRMEDRa Medical SystemsN/AN/AN/AN/ACurrent Analyst RatingsLatest QNRX, RMED, and NXGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024QNRXQuoin PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $4.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNXGLNEXGEL$2.05M7.39N/AN/A$1.37 per share1.93QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ARMEDRa Medical Systems$10K0.00N/AN/A$4.29 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNXGLNEXGEL-$4.75M-$0.48N/A∞N/A-76.64%-38.69%-25.90%4/1/2024 (Confirmed)QNRXQuoin Pharmaceuticals-$8.69M-$10.24N/A∞N/AN/A-105.09%-55.69%5/13/2024 (Estimated)RMEDRa Medical Systems-$26.86M-$92.36N/AN/AN/AN/A-496.57%-344.49%N/ALatest QNRX, RMED, and NXGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024N/ANXGLNEXGELN/AN/AN/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNXGLNEXGELN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ARMEDRa Medical SystemsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNXGLNEXGEL0.043.582.92QNRXQuoin PharmaceuticalsN/A3.153.15RMEDRa Medical SystemsN/A2.862.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNXGLNEXGEL2.21%QNRXQuoin Pharmaceuticals8.63%RMEDRa Medical Systems11.00%Insider OwnershipCompanyInsider OwnershipNXGLNEXGEL27.15%QNRXQuoin Pharmaceuticals3.30%RMEDRa Medical Systems18.62%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableNXGLNEXGEL125.72 million4.17 millionNot OptionableQNRXQuoin Pharmaceuticals4990,000954,000Not OptionableRMEDRa Medical Systems145.37 million4.37 millionNot OptionableQNRX, RMED, and NXGL HeadlinesSourceHeadlineDietary Interventions Reduce CVD Risk in RA and SpAajmc.com - March 8 at 7:57 PMAlert1 Medical Alert System Review: What Experts Say (2024)forbes.com - February 20 at 9:27 PMRa Medical Systems Inc.thestreet.com - February 15 at 10:42 AMCatheter Precision Inc (VTAK)investing.com - February 11 at 11:09 PMVTAK Catheter Precision, Inc.seekingalpha.com - January 19 at 6:41 PMWhat Is The Life Expectancy Of Rheumatoid Arthritis? A Review By Doctorsmsn.com - January 7 at 11:58 PMCatheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Qfinance.yahoo.com - August 25 at 6:53 PMReminder: Ra Medical Systems Announces Name and Ticker Symbol Changesfinance.yahoo.com - August 17 at 9:15 AMRa Medical Systems, Inc.: Ra Medical Systems Announces Allowance of New Closure Device Patentfinanznachrichten.de - August 16 at 6:14 PMRa Medical Systems Announces Milestone Achievement for Electrophysiology Divisionfinance.yahoo.com - August 7 at 12:14 PMRa Medical Systems, Inc.: Ra Medical Systems Announces Proposed Name and Ticker Symbol Changesfinanznachrichten.de - August 2 at 8:13 AMRa Medical says demand is rising for its non-invasive electrophysiology mapping systemmassdevice.com - July 24 at 5:15 PMRa Medical Systems, Inc.: Ra Medical System's Electrophysiology Division Has Increased Demand for its Non-invasive Mapping Systemfinanznachrichten.de - July 24 at 12:14 PMRa Medical System’s Electrophysiology Division Has Increased Demand for its Non-invasive Mapping Systemfinance.yahoo.com - July 24 at 12:14 PMRa Medical Systems, Inc.: RMED's LockeT Device Utilized in Structural Heart Proceduresfinanznachrichten.de - July 6 at 10:17 AMRMED's LockeT Device Utilized in Structural Heart Proceduresfinance.yahoo.com - July 6 at 10:17 AMInvesting in Ra Medical Systems Inc (RMED): What You Must Knowknoxdaily.com - July 5 at 6:18 PMRa Medical Systems, Inc.: RMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023finanznachrichten.de - June 28 at 9:07 AMRMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023finance.yahoo.com - June 28 at 9:07 AMRa Medical Systems, Inc.: Ra Medical's Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO Systemfinanznachrichten.de - June 12 at 4:10 PMRa Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO Systemfinance.yahoo.com - June 12 at 4:10 PMMedical Device Co. Completes Merger in Q1/23investorideas.com - June 9 at 9:35 PMRa Medical Systems reports Q1 resultsmsn.com - June 5 at 10:34 AMRa Medical Systems, Inc.: Ra Medical Systems Announces First Quarter Resultsfinanznachrichten.de - June 2 at 9:16 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks McCormick & Company Stock Isn’t Cheap, But It Is UndervaluedMarch 26, 2024 10:28 AMView McCormick & Company Stock Isn’t Cheap, But It Is UndervaluedGeneral Mills Stock Price Reversal Gains Momentum on Good NewsMarch 20, 2024 9:30 AMView General Mills Stock Price Reversal Gains Momentum on Good NewsEnergy Sector Nears Multi-Year Resistance: Breakout Ahead?March 21, 2024 8:45 AMView Energy Sector Nears Multi-Year Resistance: Breakout Ahead?All Headlines Company DescriptionsNEXGELNASDAQ:NXGLNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Quoin PharmaceuticalsNASDAQ:QNRXQuoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.Ra Medical SystemsNYSE:RMEDRa Medical Systems, Inc develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. Ra Medical Systems, Inc is based in Fort Mill, South Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.